1. Academic Validation
  2. Toward Structurally Novel and Metabolically Stable HIV-1 Capsid-Targeting Small Molecules

Toward Structurally Novel and Metabolically Stable HIV-1 Capsid-Targeting Small Molecules

  • Viruses. 2020 Apr 16;12(4):452. doi: 10.3390/v12040452.
Sanjeev Kumar V Vernekar 1 Rajkumar Lalji Sahani 1 Mary C Casey 2 Jayakanth Kankanala 1 Lei Wang 1 Karen A Kirby 3 Haijuan Du 3 Huanchun Zhang 3 Philip R Tedbury 3 Jiashu Xie 1 Stefan G Sarafianos 3 Zhengqiang Wang 1
Affiliations

Affiliations

  • 1 Center for Drug Design, College of Pharmacy, University of Minnesota, Minneapolis, MN 55455, USA.
  • 2 Department of Molecular Microbiology and Immunology, University of Missouri School of Medicine, Christopher S. Bond Life Sciences Center, Columbia, MO 65211, USA.
  • 3 Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA 30322, USA.
Abstract

HIV-1 capsid protein (CA) plays an important role in many steps of viral replication and represents an appealing Antiviral target. Several CA-targeting small molecules of various chemotypes have been studied, but the peptidomimetic PF74 has drawn particular interest due to its potent Antiviral activity, well-characterized binding mode, and unique mechanism of action. Importantly, PF74 competes against important host factors for binding, conferring highly desirable Antiviral phenotypes. However, further development of PF74 is hindered by its prohibitively poor metabolic stability, which necessitates the search for structurally novel and metabolically stable chemotypes. We have conducted a pharmacophore-based shape similarity search for compounds mimicking PF74. We report herein the analog synthesis and structure-activity relationship (SAR) of two hits from the search, and a third hit designed via molecular hybridization. All analogs were characterized for their effect on CA hexamer stability, Antiviral activity, and cytotoxicity. These assays identified three active compounds that moderately stabilize CA hexamer and inhibit HIV-1. The most potent analog (10) inhibited HIV-1 comparably to PF74 but demonstrated drastically improved metabolic stability in liver microsomes (31 min vs. 0.7 min t1/2). Collectively, the current studies identified a structurally novel and metabolically stable PF74-like chemotype for targeting HIV-1 CA.

Keywords

HIV-1; PF74; capsid-targeting antivirals; metabolic stability.

Figures
Products